Neuronetics Announces CFO Transition and Reaffirms 2026 Guidance
Neuronetics, Inc. Announces CFO Transition and Reaffirms Fiscal Year 2026 Financial Guidance
Key Points for Investors
- Executive Transition: Steven E. Pfanstiel, Executive Vice President, Chief Financial Officer, and Treasurer, will be leaving Neuronetics, Inc. to pursue an opportunity outside the company. He will remain through May 1, 2026, to ensure an orderly transition.
- No Disputes Leading to Departure: The company has clarified that Mr. Pfanstiel’s resignation is not due to any disagreement with management, the Board, or company policies.
- CFO Search Underway: Neuronetics has initiated a search for Mr. Pfanstiel’s successor.
- Guidance Reaffirmed: In conjunction with the transition announcement, Neuronetics reaffirmed its previously issued fiscal year 2026 financial guidance, originally provided during its Q4 2025 earnings call on March 17, 2026.
Company Overview and Strategic Position
Neuronetics, Inc. (NASDAQ: STIM) is a medical technology company specializing in neurohealth disorders. As the maker of NeuroStar® Advanced Therapy, Neuronetics delivers non-drug, noninvasive treatments for patients with major depressive disorder (MDD) and other mental health conditions, especially when traditional medications have failed. The company also operates Greenbrook TMS Inc. treatment centers across the United States, offering both NeuroStar Advanced Therapy and SPRAVATO® (esketamine nasal spray) for treatment-resistant depression and MDD with acute suicidal ideation or behavior.
NeuroStar Advanced Therapy is recognized as the leading transcranial magnetic stimulation (TMS) system for MDD in adults. It is supported by the largest clinical data set and outcomes registry for any TMS treatment system. The company emphasizes its focus on delivering innovative, effective in-office treatments for neurohealth conditions.
The NeuroStar Advanced Therapy System is FDA-cleared for multiple indications, including:
- Treatment of adults with MDD
- Adjunctive treatment of adults with obsessive-compulsive disorder
- Reduction of anxiety symptoms in adults with comorbid anxious depression
- First-line adjunctive treatment of MDD in adolescent patients aged 15-21
For full safety information and indications for use, investors and clinicians are directed to NeuroStar.com.
Forward-Looking Statements and Risks
The company’s press release contains forward-looking statements regarding its financial outlook and business strategy. These statements are subject to a variety of risks and uncertainties, including but not limited to:
- The impact of the Greenbrook transaction on business relationships and operating results
- Ability to execute business strategy and achieve profitable operations
- Dependency on sales and usage of the NeuroStar Advanced Therapy System
- Salesforce efficacy, talent retention, and reimbursement coverage
- Development of competing technologies and therapies
- Regulatory developments and the outcome of clinical trials
- Ability to roll out new programs and maintain positive cash flow
Investors are encouraged to review the company’s filings with the SEC for a comprehensive assessment of these risks.
Potential Share Price Implications
Shareholders should note the following potentially price-sensitive developments:
- The unexpected departure of a Chief Financial Officer can raise concerns about leadership stability, but the company’s statement that there was no dispute or disagreement should provide some reassurance.
- Reaffirmation of 2026 financial guidance helps to maintain investor confidence and may offset uncertainty related to the executive change.
- Ongoing risks related to execution, competition, reimbursement, and regulatory changes remain, as outlined in the company’s forward-looking statements.
The combination of executive transition and guidance reaffirmation could lead to volatility in the company’s share price, depending on investor perception of management’s ability to maintain performance and execute strategic plans during this period of change.
Contact Information
References and Further Information
- For more on SPRAVATO® safety and indications, visit spravatohcp.com.
- SEC filings and risk factors can be found at sec.gov.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should review official SEC filings and consult with their financial advisors before making any investment decisions. The author assumes no responsibility for any losses arising from reliance on the information provided above.
View EXPONENT INC Historical chart here
